|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations显示文摘For patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the relationship between the dose or duration of treatment with tyrosine kinase inhibitor (TKI) and overall survival remains unclear. Here, we analyzed clinical data of 39 patients who were diagnosed with EGFR mutation-positive non-small cell lung cancer and treated with TKI, but subsequently died. Several parameters were measured in this study: overall survival; first, second, and overall TKI therapy durations; first TKI intensity (actual dose/normal dose); and TKI rate (overall TKI therapy duration/overall survival). The response rate to TKI therapy was 50% , and the median survival was 553 days. After TKI therapy failed, 38.5% patients were re-challenged with TKI. We observed a moderate relationship [r = 0.534, 95% confidential interval (CI) = 0.263 to 0.727, P < 0.001] between overall TKI therapy duration and overall survival. However, we found no relationship between overall survival and first TKI intensity (r = 0.073, 95% CI = -0.380 to 0.247, P = 0.657) or TKI rate (r = 0.0345, 95% CI = -0.284 to 0.346, P = 0.835). Nonsmall cell lung cancer patients with mutation-positive tumors remained on TKI therapy for, on average, 33% of the overall survival time. These findings suggest that patients with EGFR mutation-positive tumors should not stick to using TKIs. | Hidekazu Suzuki Tomonori Hirashima Norio Okamoto Tadahiro Yamadori Motohiro Tamiya Naoko Morishita Takayuki Shiroyama Tomoyuki Otsuka Kanako Kitai Ichiro Kawase | 2013 | Chinese Journal of Cancer2013，32，3： | 3 |
| 2 | Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas显示文摘 | Shigemasa K Shiroyama Y Sawasaki T | 2001 | Int J Oncol2001，18，5： | 1 |
| 3 | Focal macular electroretinogram in severe myopia显示文摘 | Ishikawa M Miyake Y Shiroyama N | 1990 | Acta Sci Ophthalmol Jpn1990，94，： | 1 |
| 4 | Phase II study of S-1 monotherapy in platinum-refractory, ad- vanced non-small cell lung cancer显示文摘 | Shiroyama T Komuta K Imamura F | 2011 | Lung Cancer2011，74，1： | 1 |
| 5 | Fracture mechanics and toughening mechanisms analysis of Ce - Tzp/Al2O3 nanoeomposite for biomedical applications 显示文摘 | PEZZOTTI G YAMADA K SHIROYAMA S | 2007 | Key Engineering Materials2007，，1： | 1 |
| 6 | Phase Ⅱ study of S-1 monotherapy in platinum-refractory,advanced non-small cell lung cancer显示文摘 | Shiroyama T Komuta K Imamura F | | 0，，01： | 1 |
| 7 | Pharmacokinetic and pharmacodynamic studies following pereutaneous absorption of erythropoietin micropiles to rats显示文摘 | Shiroyama Y Yoshimitsu Y Ohashi J | 2007 | J Controlled Release2007，121，： | 1 |
| 8 | Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-smal celllung cance显示文摘 | Minami S Kijima T Shiroyama T | | 0，，： | 1 |
| 9 | Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas显示文摘 | Shigemasa K Shiroyama Y Sawasaki T | 2001 | Int J Oncol2001，18，5： | 1 |
| 10 | Focal macular eletroretinogram in severe myopia显示文摘 | Ishikawa M Miyake Y Shiroyama N | | 0，，： | 1 |
| 11 | The case study of the sabo CSG method ( in Japanese) 显示文摘 | Hirushi Hagiwara Yukinobu Ohtahahara Masayoshi Shiroyama | 2000 | Journal of JSECE2000，53，1： | 1 |
| 12 | Phase II study of S-1monotherapy in platinum-refractory,advanced non-small cell lung cancer显示文摘 | Shiroyama T Komuta K Imamura F | | 0，，01： | 1 |
| 13 | Selfdissolving microneedles for the percutaneous absorption of EPO in mice 显示文摘 | Ito Y Yoshimitsu J I Shiroyama K Sugioka N Takada K | 2006 | J Drug Target2006，14，： | 1 |
| 14 | Increased MCL- 1 expression is associated with poor prognosis in ovarian carcinom显示文摘 | Shigemasa K Katoh O Shiroyama Y | 2002 | Jpn J Cancer Res2002，93，5： | 1 |
| 15 | Efficacy and adverse effects of bromfenac ophthalmic solution following cataract surgery显示文摘 | Takamatsu F Shiroyama N Saito Y | 2003 | Rinsho Ganka (Jpn J Clin Ophthalmol)2003，11，8： | 1 |
| 16 | Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas 显示文摘 | Shigenmasa K Katoh O Shiroyama Y | 2002 | Jpn J Cancer Res2002，93，5： | 1 |
| 17 | 显示文摘 | shiroyama T Nakamura R | 1992 | Phys Rev B1992，45，： | 1 |
| 18 | Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread显示文摘 | Shibata T Uchida H Shiroyama T | 2016 | Gene Therapy2016，23，6： | 1 |
| 19 | Underexpression of cyclin-dependent kinase inhibitor P27 is associated with poor prognosis in serous ovarian carcinomas 显示文摘 | Shigemasa K Shiroyama Y Sawasaki T | 2001 | Int J Oncol2001，18，5： | 1 |
| 20 | Underexpression of cyclin-dependent kinase inhibitor P27 is associated with poor prognosis in serous ovarian cancinomas显示文摘 | Shigemass K Shiroyama Y Sawasaki T | 2001 | Int J Oncol2001，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员